

AN INTERNATIONAL COMPETITION WHICH PROMOTES THE MOST PROMISING INNOVATIONS IN LIFE SCIENCES




OCTOBER 3rd, 2017
Pavillon Dauphine - Paris

Every year since 2009, the Innovation Prize rewards the most promising start-ups (<8 years old) and the best academic research teams, which are currently developing a cutting edge project in the area of life sciences (Biotech, Medtech, m/e-health, diagnostics).

SELECTION PROCESS

A jury of experts assesses the projects on the basis of 5 criteria:

- Scientific quality of the innovation,
- Level of the intellectual property,
- Quality of the Human Resources,
- Project feasibility,
- Chances of success on the market/Investor interest.





The jury consists in a panel of international experts working in the pharmaceutical and academic fields:

- Marc GITZINGER – *Bioversys*,
- Michel SESTIER – *Servier*,
- Antony LEBEAU – *ANR*,
- Pierre LEGRAIN – *Institut Pasteur*,
- Rafi MARDACHTI – *Universal Medica Group*,
- Mallory PERRIN-WOLFF – *Institut Pasteur*,
- Chantal VERNIS – *SATTLutech*,
- Nader YAGHOUBI – *PathMaker Neurosystems*.


THE INNOVATION PRIZE 2017 PROVIDES PARTICIPANTS WITH THE OPPORTUNITY

- To be awarded up to €30 000 in financial endowment and free consulting services (for each of the 3 prize-winners)
- To gain more exposure among the professionals in their sector (including a pitch session for the 9 finalists)
- To benefit from an in-depth assessment of their project by a jury of experts
- To form partnerships key to their future development


A STRONG DIVERSITY OF TECHNOLOGIES



A COMPETITION FOCUSED ON R&D STAGE



262 CANDIDATES IN 2017



FINALISTS 2017

BIOTECH


Miguel PRUDENCIO 

New vaccine against malaria

 ROPLAVAC has developed an innovative immunization strategy against human malaria, employing a genetically modified rodent malaria parasite as a safe, efficient and versatile vaccination platform.


Alex ZWYER 

Mazindol - A Game Changer for the Treatment of ADHD & Narcolepsy

 NLS is repurposing and reformulating the wake-promoting agent Mazindol, previously indicated for short term obesity, in order to treat both Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Younes LAZRAK 


C4Diagnostics

 C4Diagnostics develops breakthrough in vitro diagnostics for infectious by specifically tagging the agent surface of legionnaire's disease and urinary tract infection. The patented technology of C4Diagnostics makes it possible to covalently attach conventional tags onto the agent surface allowing concentration and/or much faster detection than traditional cell culture.

MEDTECH


Raphaël BLANC 

Optima (Active Catheter from BaseCampVascular)

 BaseCamp Vascular (BCV) is a start-up company developing an active catheter, based on shape memory, with an orientable tip for endovascular procedures.

Elizabeth BLAKE 

MARIA

 Micrima, with its MARIA™ breast imaging system based on radiowaves, positions itself as a safer, less invasive and quicker alternative to X-ray mammography, in the detection of breast cancer.

Daria LEMANN-BLUMETHAL 


Direct Selective Trabeculoplasty for Glaucoma Treatment

 With a high-resolution image-acquisition algorithm, BELKIN Laser Ltd is developing a unique automatic, painless and fast glaucoma laser treatment.

DIGITECH


Alessandro SCOZZESI 

I-VITAE

 With their science-based digital platform, D-NAMIC S.R.L empowers women with fertility issues to conceive naturally whilst avoiding Assisted Reproductive Treatments.

Geoffroy VERGEZ 

MyCurieSein

 Observia offers an innovative mobile application, MyCurieSein, which prevents isolation, educates and motivates patients going back post breast cancer diagnosis and surgery.


Francisco Javier ANDRADE 

CreatSens

 UNIVERSITAT ROVIRA I VIRGILI CreatSens are innovative low-cost paper-based sensors which monitor kidney function and relays the data to health professionals.

Pierre-Marie GIROD-ROUX 

Sinnovaction

 Understanding the urgent need for predicting a patient's answer to biologics treatment in Rheumatology, SINNOTEST will be able to select the best treatment with the highest probability of patient's response in RA and AS.

Come and meet our participants and finalists
on the 3rd of October 2017 at Pavillon Dauphine in Paris

CONTACT:

Aurélia RINGARD - +33 (0) 1 41 12 27 71 - aurelia.ringard@universalmedica.com

Rafi MARDACHTI - rafi.mardachti@universalmedica.com

For more information: www.universal-biotech-prize.com

Follow us:



An event
organized by:

